Skip to main content
. 2020 Apr 3;38(5):1588–1597. doi: 10.1007/s10637-020-00930-5

Table 3.

Treatment-related adverse events (as-treated population)

TAS-114/S-1
(n = 64)
S-1
(n = 63)
All Grades ≥Grade 3 All Grades ≥Grade 3
Event n (%) n (%) n (%) n (%)
All 60 (93.8) 35 (54.7) 57 (90.5) 10 (15.9)
Hematology
Anemia 37 (57.8) 14 (21.9) 10 (15.9) 0
White blood cell count decreased 10 (15.6) 2 (3.1) 5 (7.9) 0
Platelet count decreased 8 (12.5) 1 (1.6) 6 (9.5) 0
Neutrophil count decreased 6 (9.4) 2 (3.1) 7 (11.1) 1 (1.6)
Non-hematology
Decreased appetite 25 (39.1) 3 (4.7) 22 (34.9) 1 (1.6)
Nausea 20 (31.3) 0 20 (31.7) 1 (1.6)
Diarrhea 18 (28.1) 2 (3.1) 12 (19.0) 1 (1.6)
Skin hyperpigmentation 18 (28.1) 0 11 (17.5) 0
Maculo-papular rash 18 (28.1) 4 (6.3) 2 (3.2) 0
Asthenia 17 (26.6) 4 (6.3) 9 (14.3) 2 (3.2)
Rash 15 (23.4) 5 (7.8) 3 (4.8) 0
Vomiting 10 (15.6) 0 11 (17.5) 2 (3.2)
Pruritus 10 (15.6) 0 7 (11.1) 0
Stomatitis 9 (14.1) 1 (1.6) 4 (6.3) 0
Malaise 8 (12.5) 0 5 (7.9) 0
Fatigue 6 (9.4) 1 (1.6) 9 (14.3) 1 (1.6)
Dry skin 9 (14.1) 0 5 (7.9) 0